Philips completes the acquisition of BioTelemetry, Inc.

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that it has completed the acquisition of BioTelemetry, Inc. (NASDAQ: BEAT), a leading U.S.-based provider of remote cardiac diagnostics and monitoring. BioTelemetry’s financial results will be consolidated as part of Philips’ Connected Care business segment as of February 9, 2021.

The acquisition of BioTelemetry is a strong fit with Philips’ cardiac care portfolio, and its strategy to transform the delivery of care along the health continuum with integrated solutions. Philips’ patient care management solutions for the hospital include real-time patient monitoring, therapeutic devices, telehealth and informatics. Moreover, Philips has an advanced and secure cloud-based Philips HealthSuite digital platform optimized for the delivery of health care across care settings.

With 2020 sales of USD 450 million, BioTelemetry adds a complete range of clinically validated ambulatory cardiac diagnostics and monitoring services: Short-term Holter monitoring services, Long-term Holter monitoring services, Event recorder services, and Mobile Cardiac Outpatient Telemetry (MCOT) services. BioTelemetry has built one of the world's largest remote cardiac monitoring services networks, providing services for over one million patients per year. Additionally, BioTelemetry has a clinical research business that provides testing services for clinical trials.

"The combination of Philips' leading patient care management portfolio in the hospital with BioTelemetry's leading cardiac diagnostics and monitoring portfolio outside the hospital will result in a global leader in patient care management solutions for the hospital and the home for cardiac and other patients," said Frans van Houten, CEO of Royal Philips. "With our collective portfolios, and our healthcare informatics and services platforms, we will be in an optimal position to improve patient care across care settings for multiple diseases and medical conditions."

Financials

BioTelemetry and its approximately 1,900 employees will become part of Philips' Connected Care business segment. The acquisition is projected to be nominal sales growth and adjusted EBITA margin [1] accretive for Philips in 2021. Philips targets significant synergies driven by cross-selling opportunities, geographical expansion, and portfolio innovation synergies, such as Philips’ HealthSuite digital platform. Additionally, Philips will drive operational performance improvements through its proven productivity programs. The BioTelemetry business is expected to grow double-digits and to improve its Adjusted EBITA margin to more than 20% by 2025.

Transaction

The acquisition of BioTelemetry was structured as a merger under Section 251(h) of the General Corporation Law of the State of Delaware following the successful completion of Philips' previously announced tender offer to purchase all outstanding shares of common stock of BioTelemetry for USD 72.00 per share in cash, without interest, less any applicable withholding taxes. As a result of the merger, all remaining BioTelemetry shares were converted into the right to receive USD 72.00 per share in cash, without interest, less any applicable withholding taxes.

BioTelemetry has requested that NASDAQ files a Form 25 with the United States Securities and Exchange Commission causing the delisting of BioTelemetry’s common stock from NASDAQ. BioTelemetry’s common stock ceased trading prior to the opening of trading on February 9, 2021.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries.

About BioTelemetry

BioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The company provides remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers.

1. Adjusted EBITA is defined as income from operations excluding amortization of acquired intangible assets, impairment of goodwill and other intangible assets, restructuring charges, acquisition-related costs and other significant items.

Most Popular Now

Artificial Intelligence in Healthcare Re…

This study presents an overview of the development, adoption and use of Artificial Intelligence (AI) technologies and applications in the healthcare sector across all Member States. The main aim of...

New App Helps Parents Identify Treatable…

A ground-breaking new, mobile phone app, 'GrowthMonitor' places the accurate measurement of children's height in the hands of parents and carers. Preliminary data to be presented at the Society for...

Dedalus Acquires Swiftqueue to Support P…

Dedalus Group ("Dedalus"), a leading international healthcare software solutions provider, has announced to have completed the acquisition of 100% of Swiftqueue Technologies Ltd a fast-growing cloud-native appointment and scheduling solution...

Bittium Exhibits its High-Tech Medical T…

Bittium exhibits its innovative products and solutions for cardiology and neurophysiology as well as R&D services for the development of medical and healthcare technology at the MEDICA 2021 event. It...

Development of AI Technology for Produci…

Transcranial focused ultrasound can be used to treat degenerative movement disorders, intractable pain, and mental disorders by delivering ultrasound energy to a specific area of the brain without opening the...

FDA Authorizes Marketing of Virtual Real…

The U.S. Food and Drug Administration today authorized marketing of EaseVRx, a prescription-use immersive virtual reality (VR) system that uses cognitive behavioral therapy and other behavioral methods to help with...

Tulane University Study Uses AI to Detec…

A Tulane University researcher found that artificial intelligence (AI) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study...

Siemens Healthineers and UCSF Create Fir…

Siemens Healthineers and UC San Francisco have formed a research and innovation-driven collaboration to make radiological imaging greener, while improving access to and quality of radiological imaging in Northern California...

Open Call DIGITAL-2021-DEPLOY-01-HEALTH:…

The consolidation of a European framework and ecosystem of digital health solutions and services, covering technological and organisational innovation and addressing the needs of the involved stakeholders, including those of...

MEDICA 2021 + COMPAMED 2021: Holding the…

15 - 18 November 2021, Düsseldorf, Germany. This week, all of the big decision makers and professional experts from the international healthcare industry will finally be making their way to Düsseldorf...

MEDICA 2021 and COMPAMED 2021 have Far E…

15 - 18 November 2021, Düsseldorf, Germany. After their four-day run as an in-person event, MEDICA and COMPAMED have achieved extremely successful results in Düsseldorf. From 15 to 18 November 2021...

Philips Integrates MedChat's AI Capabili…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced a collaboration with USA-based MedChat to integrate MedChat's live chat and AI-driven chatbot services into Philips Patient...